Charles River Laboratories International (NYSE:CRL) Given New $215.00 Price Target at Citigroup

Charles River Laboratories International (NYSE:CRL – Free Report) had its price target raised by Citigroup from $190.00 to $215.00 in a report issued on Monday morning, Benzinga reports. They currently have a neutral rating on the medical research company’s stock. Other analysts have also issued research reports about the company. Evercore ISI decreased their price […]

Related Keywords

Canada ,United States ,America ,Jamesc Foster ,Asia Pacific ,Birgit Girshick ,Robertw Baird ,Citigroup ,Morgan Stanley ,Analyst Recommendations For Charles River Laboratories International ,Securities Exchange Commission ,Charles River Laboratories International Trading ,Charles River Laboratories International Inc ,Manufacturing Solutions ,Great West Life Assurance Co ,Raymond James Trust ,Charles River Laboratories International ,Advisor Group ,Commonwealth Of Pennsylvania Public School Empls Retrmt ,Panagora Asset Management Inc ,Research Models ,Free Report ,Moderate Buy ,River Laboratories International ,Get Free Report ,Exchange Commission ,Asset Management ,Pennsylvania Public School Empls Retrmt ,West Life Assurance ,Safety Assessment ,Charles River Laboratories International Daily ,Nyse Crl ,Crl ,Medical ,15986410 ,Boost Price Target ,Citigroup Inc ,